Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU

Sponsor
Shenzhen Maternity & Child Healthcare Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05500118
Collaborator
(none)
120
1
60
2

Study Details

Study Description

Brief Summary

With the younger patients diagnosed with asymptomatic leiomyoma, delay in the reproductive age of women, the advancement of medical technology, and the rapid development of treatment methods, there are many choices between gynecologists, gynecologists and patients because of experience and knowledge. It is not easy to make the most favorable choice for patients. This study is mainly led by a committee composed of designers, doctors, nurses and patients, and based on clinical guidelines and evidence-based medicine. Co-operating with patients with asymptomatic small leiomyoma, we want to find the influencing factors of clinical decision-making, and to establish a patient decision aid tool. We use prospective trial to verify that the use of this tool can improve patients' decision-making efficacy and further improve patient-reported outcomes.

Condition or Disease Intervention/Treatment Phase
  • Other: Patients Decision Aids

Study Design

Study Type:
Observational
Anticipated Enrollment :
120 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU
Anticipated Study Start Date :
Aug 31, 2022
Anticipated Primary Completion Date :
Aug 31, 2024
Anticipated Study Completion Date :
Aug 31, 2027

Arms and Interventions

Arm Intervention/Treatment
communication without PADs

We use traditional communication ways to discuss the conditions with patients.

communication with PADs

The committee, composed of designers, doctors, nurses and patients, bases on guidelines and evidence-based medicine to make a tool. And we use this tool to discuss the conditions with patients.

Other: Patients Decision Aids
Patient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.

Outcome Measures

Primary Outcome Measures

  1. Patient satisfaction after using PDAs [6-12 months]

    The patients in PDAs will undertake the treatment by PDAs. And we will collect the satisfaction after 12 months.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Diagnosis of leiomyoma: patients with leiomyoma diagnosed by imaging examinations (ultrasound and MRI) have no clinical symptoms;

  2. Female with age in 18-55 years old;

  3. The maximum diameter of a single leiomyoma is less than 5m, and the number does not exceed 10 by MRI;

  4. No contraindications for sedation and analgesia;

  5. Patients and their families agree to join this study, and can follow up on time.

Exclusion Criteria:
  1. History of myomectomy, including transabdominal, laparoscopic, hysteroscopy, etc.;

  2. History of connective tissue diseases or radiotherapy, especially abdominal radiotherapy;

  3. With pregnancy, acute inflammation of the reproductive tract, or other gynecological benign and malignant diseases such as endometriosis and ovarian tumors;

  4. The maximum diameter of leiomyoma is greater than or equal to 5cm;

  5. Suspected malignant tumor, such as sarcoma;

  6. Those with language communication barriers and unable to cooperate with sedative and analgesic programs;

  7. Abdominal scarring, when diagnosed by ultrasound transabdominal scan, has obvious sound attenuation (more than 10mm range).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shenzhen Maternal and Child Health Hospital Shenzhen Guangdong China 518000

Sponsors and Collaborators

  • Shenzhen Maternity & Child Healthcare Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yu Dai, Associate Professor, Shenzhen Maternity & Child Healthcare Hospital
ClinicalTrials.gov Identifier:
NCT05500118
Other Study ID Numbers:
  • 2021KFKT030
First Posted:
Aug 12, 2022
Last Update Posted:
Aug 12, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 12, 2022